| dc.contributor.author |
Karam, A. |
|
| dc.contributor.author |
Mokhbat, J. |
|
| dc.contributor.author |
Kilany, H. |
|
| dc.contributor.author |
Stephan, A. G. |
|
| dc.contributor.author |
Barbari, A. |
|
| dc.contributor.author |
Masri, M. |
|
| dc.contributor.author |
Kamel, G. |
|
| dc.contributor.author |
Khoury, W. Barakat |
|
| dc.date.accessioned |
2017-02-27T14:16:58Z |
|
| dc.date.available |
2017-02-27T14:16:58Z |
|
| dc.date.copyright |
1998 |
en_US |
| dc.date.issued |
2017-02-27 |
|
| dc.identifier.issn |
0041-1345 |
en_US |
| dc.identifier.uri |
http://hdl.handle.net/10725/5284 |
|
| dc.description.abstract |
WE have shown in a previous study that converting
renal transplant recipients from regular Sandimmun
(SIM) to the new cyclosporine A (CyA) formulation
Consupren (CON) could be achieved safely with preservation
of a good graft function, no added renal or extrarenal
toxicity, and with significant cost benefits. The present study
extends the use of CON as a primary immunosuppressant
drug utilized de novo in the immediate posttransplant
period |
en_US |
| dc.language.iso |
en |
en_US |
| dc.title |
A two-year study of the new cyclosporine formulation consupren in De Novo Renal transplant patients |
en_US |
| dc.type |
Article |
en_US |
| dc.description.version |
Published |
en_US |
| dc.author.school |
SOM |
en_US |
| dc.author.idnumber |
201000157 |
en_US |
| dc.author.idnumber |
200902719 |
en_US |
| dc.author.idnumber |
201004806 |
en_US |
| dc.author.department |
N/A |
en_US |
| dc.description.embargo |
N/A |
en_US |
| dc.relation.journal |
Transplantation Proceedings |
en_US |
| dc.journal.volume |
30 |
en_US |
| dc.journal.issue |
7 |
en_US |
| dc.article.pages |
3563–3564 |
en_US |
| dc.identifier.doi |
http://dx.doi.org/10.1016/S0041-1345(98)01136-1 |
en_US |
| dc.identifier.ctation |
Stephan, A. G., Barbari, A., Masri, M., Kamel, G., Khoury, W. B., Karam, A., ... & Kilany, H. (1998, November). A two-year study of the new cyclosporine formulation Consupren in de novo renal transplant patients. In Transplantation proceedings 30(7), 3563-3564 |
en_US |
| dc.author.email |
albert.karam@lau.edu.lb |
en_US |
| dc.author.email |
jacques.mokhbat@lau.edu.lb |
en_US |
| dc.author.email |
hala.kilani@lau.edu.lb |
en_US |
| dc.identifier.tou |
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php |
en_US |
| dc.identifier.url |
http://ku7rj9xt8c.scholar.serialssolutions.com/?sid=google&auinit=AG&aulast=Stephan&atitle=A+two-year+study+of+the+new+cyclosporine+formulation+Consupren+in+de+novo+renal+transplant+patients&id=doi:10.1016/S0041-1345(98)01136-1&title=Transplantation+proceedings&volume=30&issue=7&date=1998&spage=3563&issn=0041-1345 |
en_US |
| dc.author.affiliation |
Lebanese American University |
en_US |